Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

M&A Trends: Private Equity And 'Aspirational' Execs Pair Up In India

Executive Summary

Private equity firms partnering with senior management professionals bitten by the entrepreneurial bug to buy pharmaceutical businesses in India were some of the emerging trends highlighted by experts at a recent CPhI congress in Mumbai. Scrip covers the key conference highlights on the "maturing" Indian M&A market, including how foreign firms are shedding their older portfolios to reallocate resources to newer products.

You may also be interested in...



Adcock Divests India Unit But Firm On Low Cost Manufacturing

Adcock Ingram has divested a chunk of its Indian business to the private equity firm, Samara Capital Partners Fund II, having been weighed down by the competitive scene, but it remains upbeat on its low-cost manufacturing venture in the country.

India M&A Trends: Rational Valuations, Foreign Firms Shed Products

Rational valuations and the potential divestment of older portfolios by foreign firms were some of the key mergers and acquisitions (M&A) trends highlighted by industry experts at a recent congress in India.

Dr Reddy's buys UCB portfolio in S Asia

Dr Reddy's Laboratories has snapped up a select portfolio of UCB's established products business in India, Nepal, Sri Lanka and Maldives for INR8bn ($128m), bolstering its presence in the high growth dermatology, respiratory and paediatric segments.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC097712

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel